Glucagonoma other imaging findings: Difference between revisions

Jump to navigation Jump to search
(Mahshid)
 
Line 17: Line 17:
* It is less [[Sensitivity (test)|sensitive]] than Ga DOTATATE  [[PET scan]] with [[gadolinium]] but still useful if Ga DOTATATE is not available.
* It is less [[Sensitivity (test)|sensitive]] than Ga DOTATATE  [[PET scan]] with [[gadolinium]] but still useful if Ga DOTATATE is not available.
<gallery>
<gallery>
Image:Scintigraphy.jpg|Somatostatin receptor scintigraphy with SPECT acquisition. Area of increased uptake anterior to the left kidney and medial to the spleen, consistent with the pancreatic mass<ref name="pmid23259638">{{cite journal| author=Erdas E, Aste N, Pilloni L, Nicolosi A, Licheri S, Cappai A et al.| title=Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? | journal=BMC Cancer | year= 2012 | volume= 12 | issue=  | pages= 614 | pmid=23259638 | doi=10.1186/1471-2407-12-614 | pmc=PMC3543729 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23259638  }} </ref>


Image:Neuroendocrine-tumour-pancreas.jpg|Octreoscan.<small>Case courtesy of Radswiki rID: 11670</small>
Image:Neuroendocrine-tumour-pancreas.jpg|Octreoscan.<small>Case courtesy of Radswiki rID: 11670</small>

Latest revision as of 22:34, 30 May 2019

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma other imaging findings

CDC on Glucagonoma other imaging findings

Glucagonoma other imaging findings in the news

Blogs on Glucagonoma other imaging findings

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2], Mohammed Abdelwahed M.D[3]

Overview

Other imaging studies for glucagonoma include positron emission tomography scan and somatostatin receptor scintigraphy. Scintigraphy is less sensitive than PET scan but still useful.

Other Imaging Findings

Positron Emission Tomography

Octreoscan

References

  1. Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L; et al. (2002). "Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis". Virchows Arch. 440 (5): 461–75. doi:10.1007/s00428-002-0609-x. PMID 12021920.

Template:WH Template:WS